AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23943256
Drug: Atraumatic restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atraumatic restorative treatment (ART) using high-viscosity glass ionomer
Trial: 23943256
Drug: Ultraconservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultraconservative treatment (UCT) protocol
Trial: 15220164
Drug: CSL 30
RxNorm normalized name: CSL-689
DrugBank: CSL-689 (DB17726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSL 30 ml kg(-1)
Trial: 31504139
Drug: Ado-trastuzumab emtansine
RxNorm normalized name: Ado-Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ado-trastuzumab emtansine (T-DM1) at 3.6 mg/kg intravenously every 3 weeks until toxicity or disease progression
Trial: 28454060
Drug: Conventional O2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional O2 therapy (control)
Trial: 26409117
Drug: Gastroretentive gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gastroretentive gabapentin (G-GR, 1800 mg)
Trial: 21572124
Drug: sialyl-TN (STn)
RxNorm normalized name: sialyl Lewis A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sialyl-TN (STn) keyhole limpet hemocyanin (KLH) vaccine
Trial: 21572124
Drug: 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg KLH plus adjuvant (control group)
Trial: 1616214
Drug: Norfloxacin, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin, 400 mg, twice daily for 5 days
Trial: 6232402
Drug: 10-micrograms dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-micrograms dose of HBsAg vaccine administered at 0, 1, and 6 months
Trial: 6232402
Drug: 10-micrograms dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-micrograms dose of HBsAg vaccine
Trial: 29455305
Drug: Active LASER
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active LASER (904 nm, 60 mW, 250 Hz, 3.6 J per diode, total dose of 129.6 J)
Trial: 27578220
Drug: Adjunctive metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive metformin therapy (in addition to insulin)
Trial: 23928867
Drug: Insulin alone
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin alone (control group)
Trial: 27578220
Drug: Adjunctive metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive metformin therapy
Trial: 20696421
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment program
Trial: 10790249
Drug: Treatment music
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment music tape (TT)
Trial: 8864317
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 7.5 mg single oral dose after stopping SASP for 2 weeks
Trial: 8864317
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 7.5 mg weekly + 2000 mg SASP daily
Trial: 20087340
Drug: Drugs (888
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs (888 drugs connected to side effects)
Trial: 20087340
Drug: Placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration (199 drugs)
Trial: 18593998
Drug: BMS-275183 administered
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS-275183 administered under fasting conditions (A)
Trial: 18593998
Drug: BMS-275183 administered
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS-275183 administered after a low-fat meal (B)
Trial: 18593998
Drug: BMS-275183 administered
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS-275183 administered after a high-fat meal (C)
Trial: 18593998
Drug: BMS-275183 administered
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS-275183 administered with BSA-normalized dosing (D)
Trial: 12521503
Drug: Prostin gel
RxNorm normalized name: Prostin VR
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostin gel (instant release prostaglandin gel)
Trial: 9673744
Drug: Nebulised terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised terbutaline (cumulative dose 10 mg)
Trial: 2562913
Drug: Syrup of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syrup of ipecac and activated charcoal
Trial: 30861998
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care + conventional physical therapy
Trial: 30106636
Drug: Pertuzumab plus
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pertuzumab plus trastuzumab and an aromatase inhibitor (AI)
Trial: 27401244
Drug: Tivozanib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivozanib plus mFOLFOX6 (1.5 mg orally once daily for 21 days)
Trial: 27401244
Drug: Bevacizumab plus
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab plus mFOLFOX6 (5 mg/kg intravenously every 2 weeks)
Trial: 23909813
Drug: Sorbitol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorbitol (10 g)
Trial: 23909813
Drug: Mannitol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol (10 g)
Trial: 19579757
Drug: Total transfused
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total transfused blood volume greater than 30 mL over 30 days
Trial: 17210036
Drug: Adenosine A(2A)
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine A(2A) receptor agonist/adenosine A(3) receptor antagonist (50 micro g), administered twice daily for 7 days
Trial: 17210036
Drug: Intranasal fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal fluticasone proprionate nasal spray (FPANS), administered twice daily for 7 days
Trial: 9413755
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic prophylaxis (sterile urine group)
Trial: 9413755
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment (urinary tract infection group)
Trial: 31489650
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg PTX in 3 divided doses plus 25 mg captopril 3 times a day
Trial: 31489650
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg captopril in 3 divided doses
Trial: 30359047
Drug: Interactive Voice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive Voice Response (IVR) system for daily monitoring of illicit opioid use
Trial: 28723843
Drug: High carbohydrate
RxNorm normalized name: High carbohydrate food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High carbohydrate (CHO) manipulation (414 ± 2.4 g)
Trial: 28723843
Drug: Low carbohydrate
RxNorm normalized name: Low carbohydrate beer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low carbohydrate (CHO) manipulation (79.5 ± 1.0 g)
Trial: 29239242
Drug: Fluconazole-loaded solid
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole-loaded solid lipid nanoparticles (FLZ-SLNs) topical gel
Trial: 29239242
Drug: Candistan® 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candistan® 1% cream (control)
Trial: 22784254
Drug: Methimazole (MMI)
RxNorm normalized name: Methimazole
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methimazole (MMI) treatment in Graves' disease patients
Trial: 21820424
Drug: Propylthiouracil (PTU)
RxNorm normalized name: Propylthiouracil
DrugBank: Propylthiouracil (DB00550)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propylthiouracil (PTU) treatment
Trial: 22784254
Drug: MMI treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMI treatment
Trial: 17575805
Drug: Highly purified
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highly purified omega-3 polyunsaturated fatty acids (PUFAs) at a dose of 1 g/day
Trial: 17575805
Drug: Standard secondary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard secondary pharmacological prevention therapy (anti-platelet agents, statins, beta-blockers, ACE inhibitors)
Trial: 10894877
Drug: Daniplestim (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daniplestim (2.5 microgram/kg/d) plus G-CSF (10 microgram/kg/d)
Trial: 10894877
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus G-CSF (10 microgram/kg/d)
Trial: 8931033
Drug: Calcium citrate
RxNorm normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium citrate solution (500 mg Ca2+)
Trial: 8931033
Drug: Calcium lactogluconate/carbonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium lactogluconate/carbonate solution (500 mg Ca2+)
Trial: 8931033
Drug: Calcium citrate
RxNorm normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium citrate suspension (500 mg Ca2+)
Trial: 3917619
Drug: Active surveillance
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active surveillance (weekly telephone contact)
Trial: 30328956
Drug: CBD 150
RxNorm normalized name: CBD
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CBD 150 mg
Trial: 27776675
Drug: Problem Recognition
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem Recognition Questionnaire (PRQ) pre-treatment
Trial: 27776675
Drug: Problem Recognition
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem Recognition Questionnaire (PRQ) post-treatment
Trial: 17913408
Drug: Soy isoflavone
RxNorm normalized name: soy isoflavone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavone extract (250 mg of standardized soy extract, total of 100 mg/day of isoflavone)
Trial: 15643102
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg fluoxetine capsules administered rectally
Trial: 15643102
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg fluoxetine capsules administered orally
Trial: 15643102
Drug: Rectal route
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal route of administration
Trial: 11788642
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg oral dexamethasone test
Trial: 11788642
Drug: 0.0035 mg
RxNorm normalized name: menthol 0.0035 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0035 mg oral dexamethasone per kg
Trial: 11788642
Drug: 0.0070 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0070 mg oral dexamethasone per kg
Trial: 11788642
Drug: 0.015 mg
RxNorm normalized name: sulfur 0.015 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.015 mg oral dexamethasone per kg
Trial: 11788642
Drug: All variable-dose
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All variable-dose tests
Trial: 10784385
Drug: Corn oil
RxNorm normalized name: Corn Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn oil diet (80 g of corn oil, 20 mg alpha‐tocopherol, 100 mg gamma‐tocopherol)
Trial: 10784385
Drug: Olive/sunflower oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive/sunflower oil diet (80 g of olive/sunflower oil, 24 mg alpha‐tocopherol, 2.4 mg gamma‐tocopherol)
Trial: 7746909
Drug: Salbutamol powder
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol powder (1.6 mg) from the Diskhaler
Trial: 7746909
Drug: Salbutamol nebulizer
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol nebulizer solution (2.5 ml, 1 mg ml‐1) from a jet nebulizer
Trial: 6785790
Drug: Chlorpromazine (CPZ)
RxNorm normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (CPZ) at fixed doses (200, 400, or 600 mg)
Trial: 23420053
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (stapling/suturing)
Trial: 8393637
Drug: Atrial Natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial Natriuretic Peptide (ANP) infusion at 5 ng/kg/min
Trial: 8393637
Drug: Atrial Natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial Natriuretic Peptide (ANP) infusion
Trial: 2947777
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg DMPA
Trial: 2947777
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg DMPA
Trial: 20123224
Drug: Oxygen supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen supplementation at 2 L/min via nasal cannulae overnight
Trial: 16363902
Drug: Balloon Angioplasty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balloon Angioplasty with adjunctive endovascular brachytherapy (BA+EVBT)
Trial: 12225549
Drug: Postnatal MgSO(4)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postnatal MgSO(4) infusion (250 mg/kg per day) for 3 days
Trial: 12225549
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no MgSO(4) infusion)
Trial: 7883833
Drug: Desipramine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine (75 mg, orally)
Trial: 25738891
Drug: Web-based counselor-assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based counselor-assisted family problem-solving therapy (CAPS)
Trial: 11850141
Drug: Nitrous oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrous oxide (active doses)
Trial: 11850141
Drug: No-drug option
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-drug option
Trial: 28225313
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel 2% (Tgel) 23 mg/day, uptitrated to 46 mg/day after 2 weeks if necessary, with further adjustments possible on Days 21, 42, and 63.
Trial: 28225313
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel 2% (Tgel)
Trial: 21813914
Drug: Lactate (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactate (120 mg/kg body mass)
Trial: 19114909
Drug: Furosemide (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (0.5 mg/kg/hr)
Trial: 15837997
Drug: BMS‐275291, 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS‐275291, 1,200 mg orally daily
Trial: 7605852
Drug: Naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg b.d. for 4 weeks
Trial: 7605852
Drug: Etodolac 400
RxNorm normalized name: etodolac 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etodolac 400 mg b.d. for 4 weeks
Trial: 378040
Drug: Triprolidine 2.5
RxNorm normalized name: triprolidine 2.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triprolidine 2.5 mg t.i.d.
Trial: 378040
Drug: Triprolidine 1.25
RxNorm normalized name: TRIPROLIDINE 1.25MG/5ML ORAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triprolidine 1.25 mg t.i.d.
Trial: 30565155
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg enteric-coated aspirin once daily
Trial: 28207724
Drug: Green Prescription
RxNorm normalized name: acid green 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green Prescription plus Kia Ākina (KA/GRx)
Trial: 28207724
Drug: Green Prescription
RxNorm normalized name: acid green 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green Prescription alone (GRx)
Trial: 14739148
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B lipid complex (ABLC) 3 mg/kg/day every 21 days
Trial: 11465701
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (1 mg/day)
Trial: 11465701
Drug: Folinic acid
RxNorm normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Folinic acid (2.5 mg/week)
Trial: 11465701
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (1 mg/day) and Folinic acid (2.5 mg/week)
Trial: 8067370
Drug: Oral support
RxNorm normalized name: MTX Support Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral support
Trial: 8067370
Drug: No oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oral support
Trial: 20184572
Drug: L-carnitine (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (group C)
Trial: 14507127
Drug: Kinetic cavity
RxNorm normalized name: Kineticream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinetic cavity preparation (KCP)
Trial: 10090440
Drug: Antihistamines (fexofenadine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihistamines (fexofenadine or loratadine) for 2 weeks after 1 week of placebo
Trial: 8525693
Drug: Intramuscular vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular vaccination with inactivated uropathogenic bacteria (Solco‐Urovac)
Trial: 2180234
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules
Trial: 2180234
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of Ty21a Salmonella typhi vaccine in enteric-coated capsules
Trial: 2180234
Drug: Ty21a Salmonella
RxNorm normalized name: Salmonella typhi Ty21a live antigen
DrugBank: Typhoid Vaccine Live (DB11050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ty21a Salmonella typhi vaccine (both doses)
Trial: 548940
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g cefaclor orally
Trial: 548940
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g cephalexin orally
Trial: 548940
Drug: 0.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g cefaclor orally 4 times daily
Trial: 548940
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g cefaclor (single dose)
Trial: 27724923
Drug: Daily probiotics
RxNorm normalized name: Digestive Advantage Daily Probiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily probiotics (four capsules of Vivomixx®; total of 450 billion CFU/day)
Trial: 23964444
Drug: NSAIDs (diclofenac)
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NSAIDs (diclofenac) 75 mg/d with curcumin 1,000 mg/d for 3 months
Trial: 23964444
Drug: NSAIDs (diclofenac)
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NSAIDs (diclofenac) 75 mg/d with placebo
Trial: 17657838
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy of lafutidine, clarithromycin, and amoxicillin
Trial: 17657838
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy of lansoprazole, clarithromycin, and amoxicillin
Trial: 15309484
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with verteporfin
Trial: 11792748
Drug: HPV testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV testing at 1.0 pg/mL threshold for ASCUS
Trial: 11792748
Drug: HPV testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV testing at 10.0 pg/mL threshold for ASCUS
Trial: 6531969
Drug: RA 27/3
RxNorm normalized name: Rubivirus rubella virus Wistar RA 27/3 whole
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RA 27/3 strain rubella vaccine (Rudivax)
Trial: 30288156
Drug: FDC tablet
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC tablet (gemigliptin/metformin SR 50/1,000 mg)